白血病·淋巴瘤最新文献

{"title":"Analysis of efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in treatment of relapsed/refractory acute myeloid leukemia","authors":"Tingting Li, Yuewen Fu, H. Ai, Qian Wang, Yongqi Wang, X. Jiao, Xudong Wei","doi":"10.3760/CMA.J.CN115356-20190826-00163","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190826-00163","url":null,"abstract":"Objective \u0000To explore the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed/refractory acute myeloid leukemia (AML). \u0000 \u0000 \u0000Methods \u0000The clinical data of 35 patients with relapsed/refractory AML treated with allo-HSCT in the Affiliated Cancer Hospital of Zhengzhou University from June 2011 to October 2018 was retrospectively analyzed. The overall survival (OS), disease-free survival (DFS), graft versus host disease (GVHD) incidence, transplantation related mortality and recurrence rate were calculated, and the risk factors affecting prognosis were analyzed. \u0000 \u0000 \u0000Results \u0000Hematopoietic reconstitution was obtained in all patients after transplantation. The 100 d incidence of grade Ⅱ-Ⅳ acute GVHD was (22.9±7.7)%, and the 3-year incidence of chronic GVHD was (49.5±10.60)%. The median follow-up time after transplantation was 14.1 months (4.2-89.4 months). In all cases, 18 cases survived (including 16 cases of DFS), and 17 cases died. Fourteen cases relapsed, and the median recurrence time was 4.7 months (2.9-32.4 months). The 3-year OS rate and DFS rate were (44.4±9.3)% and (43.0±9.5)%, respectively. Univariate analysis showed that the non-remission disease before transplantation, poor genetic risk grade before transplantation and recurrence after transplantation were the risk factors for OS (all P < 0.05). The 3-year OS rates in complete remission before transplantation group and non-remission before transplantation group were (63.2±12.0)% and (15.7±12.8)% (P = 0.025), the 3-year DFS rates were (62.2±12.3)% and (15.3±12.7)% (P = 0.028), and the 3-year recurrence rates were (28.2±10.7)% and (80.6±15.7)% (P = 0.057). The 3-year recurrence rate in genetic high-risk group was higher than that in middle-risk group and low-risk group [100.0%, (45.0±12.1)% and (14.3±13.2)%, P = 0.045]. The 3-year tansplantation related mortality was (18.7±7.7)%. \u0000 \u0000 \u0000Conclusions \u0000Allo-HSCT is an effective method for salvage treatment of relapsed/refractory AML, and recurrence is the main factor affecting survival. Reducing tumor load before transplantation is very important for reducing recurrence and improving curative effect. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, acute; Hematopoietic stem cell transplantation; Refractory; Recurrence; Prognosis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"146-152"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46319114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of clinical effect of azacitidine combined with CAG regimen on treatment of relapsed/refractory acute myeloid leukemia","authors":"Gongai Wang, Kewei Xue, Shumei Li, Y. Hao, Sha-sha Dong","doi":"10.3760/CMA.J.CN115356-20191211-00246","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20191211-00246","url":null,"abstract":"Objective \u0000To explore the clinical effect of azacitidine combined with CAG regimen on the treatment of relapsed/refractory acute myeloid leukemia (AML). \u0000 \u0000 \u0000Methods \u0000The data of 50 patients with relapsed/refractory AML (non-acute promyelocytic leukemia) in Jining No. 1 People's Hospital from September 2018 to September 2019 was retrospectively analyzed, and the patients were divided into the control group and the test group according to the different treatment drugs. The control group (28 cases) was treated with CAG regimen alone, and the test group (22 cases) was treated with azacitidine combined with CAG regimen. The total effective rate and adverse reactions of the two groups were observed after 1 course of treatment. \u0000 \u0000 \u0000Results \u0000After one course of treatment, the total clinical effective rate in the test group was 86% (19/22), and the rate in the control group was 71% (20/28), there was a statistically significant difference between the two groups (χ 2 = 5.273, P 0.05). \u0000 \u0000 \u0000Conclusion \u0000Azacitidine combined with CAG regimen in the treatment of relapsed/refractory AML can improve the clinical efficacy without increasing the adverse reactions. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, acute; Recurrence; Refractory; Azacitidine; CAG regimen","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"157-159"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47317695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute myeloid leukemia with BCR-ABL p210 fusion gene-positive: report of one case and review of literature","authors":"Justin Huang, Yanxi Han, Fang Wei, Shan-Hsiang Shen, Beili Hu, Lihua Chen","doi":"10.3760/CMA.J.CN115356-20190907-00175","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190907-00175","url":null,"abstract":"Objective \u0000To investigate the clinical characteristics of acute myeloid leukemia with BCR-ABL p210 fusion gene-positive. \u0000 \u0000 \u0000Methods \u0000The clinical characteristics of a patient diagnosed in the Second Hospital of Jiaxing were analyzed and the related literature was reviewed. \u0000 \u0000 \u0000Results \u0000BCR-ABL p210 fusion gene and Philadelphia chromosome (Ph) were detected by reverse transcription-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH). Imatinib associated with multi-drug intravenous chemotherapy resulted in poor efficacy. \u0000 \u0000 \u0000Conclusions \u0000Patient with Ph+/BCR-ABL+ acute myeloid leukemia is rare with a very poor prognosis. There is no unified standard treatment and the efficacy of tyrosine kinase inhibitors is unclear. Intravenous chemotherapy combined with hematopoietic stem cell transplantation is expected to change the prognosis. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, acute; Philadelphia chromosome; BCR-ABL fusion gene; Tyrosine kinase inhibitors","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"175-178"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47092359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse large B-cell lymphoma with thrombotic thrombocytopenic purpura: report of one case and review of literature","authors":"Qiang Zhao, Xingfang Dou, H. Bai, Shuting Zhang, Yanping Han, Haiying Zhang, L. Fu, Jing Zhang, M. He","doi":"10.3760/CMA.J.CN115356-20190620-00118","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190620-00118","url":null,"abstract":"目的 \u0000探讨弥漫大B细胞淋巴瘤（DLBCL）合并血栓性血小板减少性紫癜（TTP）的临床表现与诊治要点。 \u0000 \u0000 \u0000方法 \u0000回顾分析联勤保障部队第九四○医院新诊断的1例DLBCL并发TTP患者的诊治过程，并进行文献复习。 \u0000 \u0000 \u0000结果 \u0000该患者首先确诊DLBCL，治疗缓解4年后血小板减少突然加剧，ADAMTS13活性严重缺乏，DLBCL合并TTP诊断成立，确诊后行输注新鲜冰冻血浆及激素治疗，治疗后病情明显好转。 \u0000 \u0000 \u0000结论 \u0000DLBCL并发TTP较为少见，可能是ADAMTS13活性严重缺乏导致血小板微血栓形成，一经确诊后进行血浆置换或输注冰冻血浆，可取得较好疗效。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"187-189"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43136377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of triptolide and BET protein inhibitor JQ1 on the proliferation and apoptosis of MLL-rearranged acute myeloid leukemia cells and their mechanisms","authors":"Jinzhu Chen, Yuanfei Shi, Haijun Zhao, Xiaoming Xiong, Ye Zheng, Bing Xu","doi":"10.3760/CMA.J.CN115356-20190731-00148","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20190731-00148","url":null,"abstract":"Objective \u0000To investigate the effects of triptolide (TPL) and BET protein inhibitor JQ1 on proliferation inhibition and apoptosis induction of MLL-rearranged acute myeloid leukemia (AML) cell line MV4-11, and to explore their synergistic mechanisms. \u0000 \u0000 \u0000Methods \u0000MV4-11 cells in logarithmic growth phase were treated with different concentrations (100, 200, 300, and 400 nmol/L) of JQ1, 4 nmol/L TPL or different concentrations of JQ1 combined with 4 nmol/L TPL for 48 h. Cell proliferation was detected by CCK-8 method, apoptosis was detected by flow cytometry (FCM), mitochondrial membrane potential was detected by JC-1 method, and expressions of mitochondrial apoptosis pathway-related proteins were detected by Western blot. \u0000 \u0000 \u0000Results \u0000The 50% inhibitory concentration (IC50) value of MV4-11 cells treated with JQ1 for 48 h was (283.9±10.7) nmol/L. However, 4 nmol/L TPL significantly enhanced the inhibitory effect of JQ1 on proliferation of MV4-11 cells, the IC50 value of MV4-11 cells treated with JQ1 combined with TPL was (148.1±2.6) nmol/L, and the difference was statistically significant (t = 25.31, P = 0.029). The result of FCM assay showed that compared with the JQ1 alone group [(9.6±2.3)%, (12.6±1.4)%, (19.5±3.3)%, and (22.7±2.1)%], 4 nmol/L TPL combined with different concentrations (100, 200, 300, and 400 nmol/L) of JQ1 acted on MV4-11 cells for 48 h, the proportions of apoptotic cells were (16.4±1.9)%, (27.5±2.1)%, (32.9±3.6)%, and (35.5±3.0)%, respectively, the difference was statistically significant (F = 9.25, P < 0.01). After treated with 4 nmol/L TPL and JQ1 for 12 h, the level of cell membrane potential in MV4-11 cells was significantly lower than that of JQ1 single agent group, and the difference was statistically significant (P < 0.05). After treated by 4 nmol/L TPL combined with JQ1 for 24 h, the levels of anti-apoptotic proteins bcl-2 and Mcl-1 decreased, and the level of pro-apoptotic protein bax increased. \u0000 \u0000 \u0000Conclusion \u0000TPL can significantly enhance the proliferation inhibition and apoptosis induction effects of BET protein inhibitor JQ1 on MLL-rearranged AML cells, and the mechanism may be related to enhancing the mitochondrial apoptosis pathway. \u0000 \u0000 \u0000Key words: \u0000Gene rearrangement; Leukemia, myeloid, acute; Triptolide; BET protein inhibitor JQ1","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"153-156"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46669655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress of bispecific antibody drugs in hematological malignancies","authors":"Wei Fang, Yuqin Song","doi":"10.3760/CMA.J.CN115356-20200103-00006","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115356-20200103-00006","url":null,"abstract":"In recent years, the incidence of hematological malignancies is increasing year by year, which seriously affects the quality of life of patients. Antibody drugs are the main force of modern biological products industry, accounting for more than 50% of the global biological products market, and the application prospects of bispecific antibody drugs have attracted much attention. This article reviews the role and research progress of bispecific antibody drugs in hematological malignancies. \u0000 \u0000 \u0000Key words: \u0000Hematologic neoplasms; Antibodies, bispecific; Treatment","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"129-131"},"PeriodicalIF":0.0,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43954089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application progress of novel Bruton tyrosine kinase inhibitors in B-cell lymphoma","authors":"Donglu Zhao","doi":"10.3760/CMA.J.ISSN.1009-9921.2020.02.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2020.02.003","url":null,"abstract":"The Bruton tyrosine kinase (BTK) inhibitor ibrtinib has excellent results in B-cell lymphoma. However, there are still unmet treatment needs in clinical practice. New BTK inhibitors are highly selective and specific, reducing off-target effects. The overall response rate (ORR) of acalabrutinib combination therapy is more than 90%, and high rates of peripheral blood and bone marrow minimal residual disease (MRD)-negative are obtained. Orelabrutinib is a new domestic BTK inhibitor, the results of a phase Ⅱ study showed that the ORR in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma is 88.5%, and in mantle cell lymphoma is 82.5%. Another new domestic BTK inhibitor zanubrutinib, international multi-center study showed that ORR is 95.9% in relapsed/refractory CLL, and in treatment-naive chronic lymphocytic leukemia with del (17p) is 92.2%. In addition, non-covalent BTK inhibitors are also emerging, which are expected to overcome the problem of resistance to BTK inhibitors. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, B-cell; Protein-tyrosine kinases; Protein kinase inhibitors; Bruton tyrosine kinase","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"79-82"},"PeriodicalIF":0.0,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45242795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel strategies for treatment of follicular lymphoma","authors":"Zhang Xu","doi":"10.3760/CMA.J.ISSN.1009-9921.2020.02.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2020.02.006","url":null,"abstract":"Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma(iNHL). Rituximab combined with chemotherapy as the first-line treatment has achieved satisfactory results, but the relapse and progress still reappear after the first-line treatments. In the 61st of American Society of Hematology (ASH) Annual Meeting, more and more novel drugs including EZH2 inhibitor tazemetostat, SYK/JAK inhibitor cerdulatinib, anti-CD3-CD20 antibody mosunetuzumab and programmed death 1 inhibitor nivolumab, etc, and new strategies including rituximab combined with anti-CD20 monoclonal antibody and polatuzumab combined with obinutuzumab and lenalidomide had been reported and brought an ample and promising choices for FL patients. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, follicular; Therapy; Clinical protocols","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"91-94"},"PeriodicalIF":0.0,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44895494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological characteristics of non-Hodgkin lymphoma in Shandong province: analysis of 2 886 cases","authors":"Ti Wang, Qiujing Zhang, Yuhong Liu, Qingqing Zhu, Jujie Sun, Jianbo Zhang, Jie Liu, B. Song","doi":"10.3760/CMA.J.ISSN.1009-9921.2020.02.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2020.02.011","url":null,"abstract":"Objective \u0000To investigate the clinicopathological characteristics of non-Hodgkin lymphoma (NHL) in Shandong province. \u0000 \u0000 \u0000Methods \u0000The clinicopathological data of 2 886 NHL cases in Shandong Cancer Hospital from January 2002 to December 2017 were retrospectively analyzed, the clinicopathological characteristics of patients were summarized and compared with other regions in China and abroad. \u0000 \u0000 \u0000Results \u0000The median age of all NHL cases was 52 years old (4-90 years old), and the ratio of male to female was 1.57∶1. The subtypes distribution analysis revealed that B-cell NHL (B-NHL) accounted for 66.7% (1 925 cases) of all cases and T-cell NHL (T-NHL) accounted for 27.3% (788 cases) of all cases. The common subtypes were diffuse large B-cell lymphoma (36.0%, 1 039/2 886), NK/T-cell lymphoma (8.8%, 254/2 886), follicular lymphoma (8.2%, 237/2 886) and peripheral T-cell lymphoma (7.4%, 214/2 886). Of all the cases, the nodal lymphomas accounted for 45.8% (1 322 cases) and the extra nodal lymphomas accounted for 54.2% (1 564 cases); there were 389 patients (13.5%) with stage Ⅰ, 678 patients (23.5%) with stage Ⅱ, 975 patients (33.8%) with stage Ⅲ, and 722 patients (25.0%) with stage Ⅳ. The distribution of NHL subtypes in Shandong province was consistent with the domestic multicenter study. However, T-NHL subtype ratio was significantly higher than the foreign studies. \u0000 \u0000 \u0000Conclusions \u0000The overall incidence of NHL in Shandong province of China is dominated by middle-aged people, and the proportion of B-NHL is higher than that of T-NHL. The distribution of NHL subtypes in Shandong province of China are different from those in the European and American countries, but are roughly consistent with the domestic multicenter study. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, non-Hodgkin; Diagnosis; Pathological classification; Immunophenotyping","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"117-120"},"PeriodicalIF":0.0,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47641973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognosis of childhood acute lymphoblastic leukemia complicated with EB virus infection","authors":"Mengmeng Yin, A. Liu, A. Zhang, Ya-qin Wang","doi":"10.3760/CMA.J.ISSN.1009-9921.2020.02.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2020.02.008","url":null,"abstract":"Objective \u0000To explore the clinical features and prognosis of childhood acute lymphoblastic leukemia(ALL) complicated with EB virus (EBV) infection. \u0000 \u0000 \u0000Methods \u0000The results of detection of EBV antibody and EBV-DNA in peripheral blood mononuclear cells of 196 children with ALL diagnosed in Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from January 2015 to January 2019 were collected. According to the results, 196 children with ALL were divided into EBV infection group and non-EBV infection group. The hepatomegaly and splenomegaly, chromosome, peripheral blood routine, immunophenotyping, clinical risk, secondary infection during chemotherapy, minimal residual disease (MRD) of day 46 after chemotherapy, karyotype, and prognosis were compared between the two groups. The children were followed up until April 30, 2019. \u0000 \u0000 \u0000Results \u0000Among 196 children with ALL, EBV infection rate was 72.96% (143/196). The EBV-DNA level [median (P25, P75)] of peripheral blood mononuclear cells was 3.7×103 copies/L(1.6×103 copies/L, 8.8×103 copies/L). The incidence of hepatosplenomegaly (subcostal ≥ 5 cm) in EBV infection group was higher than that in non-EBV infected group [14.69% (21/143) vs. 3.77% (2/53), χ 2= 4.45, P= 0.035]. There was no significant difference in the number of white blood cells and the incidence of abnormal karyotype between EBV infection group and non-EBV infection group (both P > 0.05). The secondary infection rate in EBV infection group was higher than that in the non-EBV infection group [41.96% (60/143) vs.24.53% (13/53), χ2= 5.03, P= 0.025], and the remission rate of day 46 in EBV-infection group was lower than that in non-EBV infection group [80.42% (115/143) vs. 98.11% (52/53), χ2= 9.60, P= 0.020]. The recurrence rate in EBV-infection group was higher than that in non-EBV infectious group [11.89% (17/143) vs. 1.89% (1/53), χ2= 4.64, P= 0.031], and there was a significant difference in the component ratio of immunophenotyping and clinical risk between the two groups (both P < 0.05). \u0000 \u0000 \u0000Conclusions \u0000The hepatosplenomegaly in children with ALL complicated with EBV infection is obvious, the secondary infection rate is high, the remission rate is low, the recurrence rate is high, and the prognosis is poor. EBV infection may be related to immunophenotyping and clinical risk in children with ALL, and has nothing to do with the abnormal karyotypes. \u0000 \u0000 \u0000Key words: \u0000Leukemia, lymphoid; Herpesvirus 4, human; Epstein-Barr virus; Child; Clinical features; Prognosis","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"102-106"},"PeriodicalIF":0.0,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45323370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}